Sequenom and Recombine launch HerediT Universal carrier screening test

22 March 2015 (Last Updated March 22nd, 2015 18:30)

US companies Sequenom Laboratories and Recombine have launched a new HerediT Universal carrier screening test, which offers comprehensive genetic information.

US companies Sequenom Laboratories and Recombine have launched a new HerediT Universal carrier screening test, which offers comprehensive genetic information.

With the launch of HerediT, which offers comprehensive genetic information, Sequenom Laboratories expands its reach into the universal carrier screening market.

Sequenom president William Welch said: "Carrier screening remains an important part of genetic risk assessment and is now being utilised by physicians for patients planning families."

The HerediT Universal test is capable of screening more than 250 genetic diseases by analysing more than 2,000 genetic mutations.

"The test can be performed preconception or at any time during pregnancy, while current options are limited to single gene testing or tests that can identify 100 hereditary conditions."

New York University Fertility Centre programme director James Grifo said: "Though individually rare, genetic disorders are collectively common and are a significant cause of childhood mortality.

"An expanded carrier screening test provides an opportunity to look beyond a patient's family history or ethnic predispositions to particular diseases, which is increasingly valuable as the obstetrics and gynaecology (OB/GYN) physician community incorporates broader screening into its routine standard of care."

According to the company, the test can be performed preconception or at any time during pregnancy, while current options are limited to single gene testing or tests that can identify 100 hereditary conditions.

Recombine CEO Alex Bisignano said: "We are excited to collaborate with Sequenom Laboratories, the market leader in non-invasive prenatal testing, to bring this expanded carrier screening technology to the OB/GYN and maternal foetal medicine space.

"This strategic alliance will help us reach more patients, and enable them to use comprehensive genetic testing and counselling services to make informed decisions in family planning."

With a focus principally on prenatal care, Sequenom Laboratories developed a broad range of laboratory tests under the brand names HerediT, MaterniT21 PLUS, SensiGene and VisibiliT.

These tests offer early patient management information for obstetricians, geneticists, and maternal foetal medicine specialists.